Copenhagen, Denmark — August 28, 2025 — Leads & Copy — Zealand Pharma A/S (Nasdaq: ZEAL) announced its participation in several investor conferences in September 2025. Adam Lange, Vice President, Investor Relations, will host investor meetings at the Jefferies Swiss Healthcare Summit 2025 in Zürich on September 3. Adam Steensberg, President and CEO, will host meetings and participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, September 3-5. Steensberg will also host meetings and participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston, September 3-5. Lange will host meetings at the Morgan Stanley Annual Healthcare Conference in New York, September 8-10. David Kendall, Executive Vice President and Chief Medical Officer, will host meetings and present at the Bank of America Global Healthcare Conference in London, September 23-25. Lange will host meetings at the KBC Securities Life Sciences Conference in Brussels on September 25.
Zealand Pharma, founded in 1998, is focused on discovering and developing peptide-based medicines. More than 10 of their drug candidates have advanced into clinical development, with two having reached the market and three in late-stage development. The company has development partnerships with a number of pharma companies and commercial partnerships for its marketed products.
Contacts:
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: alange@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investors and Media)
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com
Source: Zealand Pharma
